First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

BACKGROUND: Infliximab (IFX) is one of the treatments of choice for corticosteroid-refractory and corticosteroid-dependent ulcerative colitis (UC). A high serum trough level of IFX (TL) is reported to be associated with sustained efficacy during maintenance treatment. As part of a phase 3 randomized...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastroenterol
Main Authors: Kobayashi, Taku, Suzuki, Yasuo, Motoya, Satoshi, Hirai, Fumihito, Ogata, Haruhiko, Ito, Hiroaki, Sato, Noriko, Ozaki, Kunihiko, Watanabe, Mamoru, Hibi, Toshifumi
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Japan 2015
Assuntos:
Original Article—Alimentary Tract
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4766223/
https://ncbi.nlm.nih.gov/pubmed/26162647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00535-015-1102-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados